Skip Navigation


Annals of Oncology Advance Access originally published online on October 9, 2006
Annals of Oncology 2007 18(1):77-81; doi:10.1093/annonc/mdl336
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/1/77    most recent
mdl336v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by André, T
Right arrow Articles by de Gramont, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by André, T
Right arrow Articles by de Gramont, A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

gastrointestinal tumors

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study

T André1,7,*, C Tournigand2,7, L Mineur3,7, R Fellague-Chebra7, M Flesch4,7, M Mabro5,7, M Hebbar6,7, S Postel Vinay1, FC Bidard1, C Louvet2,7 and A de Gramont2,7

1 Hôpital Tenon, Department of Medical Oncology, Paris
2 Hôpital Saint Antoine, Department of Medical Oncology, Paris
3 Clinique Sainte Catherine, Department of Medical Oncology, Avignon
4 Hôpital Devron, Dijon
5 Hôpital Foch, Department of Medical Oncology, Suresnes
6 Hôpital Huriez, Department of Internal Medicine, Lille
7 GERCOR (French Oncology Research Group), Paris, France

* Correspondence to: Dr T. André, Service d'Oncologie Médicale, Hôpital Tenon, 4, rue de la Chine, F-75970 Paris Cedex 20, France. Tel: +33 156 0160 21; Fax: +33 156 0173 04; E-mail: thierry.andre{at}tnn.aphp.fr

Background: Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR). Celecoxib is an anti-cyclooxygenase-2 drug with anti-neoplastic properties. In the present study, celecoxib was evaluated in combination with FOLFOX7 regimen and as a single agent in maintenance therapy.

Patients and methods: This phase II study examined for previously untreated MCR patients the stop-and-go procedure [six cycles of folinic acid, 5FU and oxaliplatin (FOLFOX7) followed by chemotherapy-free intervals (CFIs) and reintroduction at progression] with continuous administration of celecoxib (800 mg/day).

Results: Forty-four patients were included, 42 eligible: performance status (%) 0/1/2 = 45/40/15, median age 60 (31–76) years. Response rate (RR) was 43% (95% CI 28%–58%). Median progression-free survival (PFS) was 6 months; median overall survival was 15.8 months. Grade 3/4 toxicity criteria were neurotoxicity 9.5%, thrombocytopenia 21.4%, neutropenia 7.1%, diarrhea 7.1%, nausea 4.8% and vomiting 2.4%. Median CFI 1 (n = 27) duration was 3.9 months (range 2–39 months).

Conclusion: With an acceptable safety profile, celecoxib combined with FOLFOX7 achieved RR and PFS in the lower range of that obtained with FOLFOX7 alone. These results indicate the lack of synergy between FOLFOX7 and celecoxib. PFS of 6 months appears lower than PFS obtained in OPTIMOX1 study with simplified LV5FU2 in maintenance therapy.

Key words: celecoxib, colorectal metastatic cancer, 5-fluorouracil, oxaliplatin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.